Trial Profile
A Randomized, Double-blind, Parallel Group, Phase III Trial to Compare the Efficacy, Safety, and Immunogenicity of TX05 With Herceptin in Subjects With HER2 Positive Early Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Jan 2022
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Cyclophosphamide; Epirubicin; Paclitaxel
- Indications Early breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Tanvex BioPharma
- 13 Apr 2021 Status changed from active, no longer recruiting to completed.
- 05 Feb 2021 Planned End Date changed from 1 Dec 2020 to 1 Feb 2021.
- 22 May 2020 Status changed from recruiting to active, no longer recruiting.